Diamyd Shares Fall On News Of Diabetes Trial Debacle

Diamyd Medical AB lost around 40 percent of its value Monday on news that it had to jettison a Phase II/III clinical trial of Diamyd, a therapeutic vaccine in development for treating autoimmune diabetes.(BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)